KalVista terminates KVD824 Phase 2 trial over liver enzyme elevations; net loss widens to $22.3M

KalVista Pharmaceuticals, Inc.

2023-Q2 EPS reported -$1.84

Phase 2 KOMPLETE trial for KVD824 terminated due to patient liver enzyme elevations; future development uncertain.
Net loss of $22.3M ($0.90 per share) for quarter ended Oct 31, 2022 vs $19.7M ($0.80) a year ago.
Cash, cash equivalents and marketable securities at $122.3M as of Oct 31, 2022, down from $166.2M at Apr 30.
Phase 3 KONFIDENT trial for sebetralstat on track; data expected H2 2023, NDA filing planned H1 2024.
Appointed Brian J. G. Pereira, M.D., as Chairman of the Board of Directors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KalVista Pharmaceuticals, Inc. reported second fiscal quarter ended October 31, 2022 results: net income $22.3 million, EPS $(0.90) per weighted average basic and diluted share.

Period: second fiscal quarter ended October 31, 2022
Net income: $22.3 million
EPS: $(0.90) per weighted average basic and diluted share
Result: reported results

Exact text from the filing

Net loss was $22.3 million, or $(0.90) per weighted average basic and diluted share, for the three months ended October 31, 2022

View on SEC.gov

Browse all earnings releases →

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-026236

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.